Academic cancer centers are facing severe staffing shortages after three years of personnel attrition during the COVID-19 pandemic—resulting in depressed levels of patient accrual to investigator-initiated and grant-funded clinical trials.
A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.
